DK1848445T3 - Farmaceutisk sammensætning og fremgangsmåde til neoangiogenese/revaskularisering, som er anvendelige ved behandling af iskæmiske hjertesygdomme - Google Patents

Farmaceutisk sammensætning og fremgangsmåde til neoangiogenese/revaskularisering, som er anvendelige ved behandling af iskæmiske hjertesygdomme Download PDF

Info

Publication number
DK1848445T3
DK1848445T3 DK06805091.3T DK06805091T DK1848445T3 DK 1848445 T3 DK1848445 T3 DK 1848445T3 DK 06805091 T DK06805091 T DK 06805091T DK 1848445 T3 DK1848445 T3 DK 1848445T3
Authority
DK
Denmark
Prior art keywords
compound
revascularization
heart
treatment
use according
Prior art date
Application number
DK06805091.3T
Other languages
English (en)
Inventor
Ming Li
Lei The Chinese University Of Hong Kong Cheng
Hongwei Liu
Original Assignee
Lead Billion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2005/003191 external-priority patent/WO2007049088A1/en
Priority claimed from PCT/IB2005/003202 external-priority patent/WO2007049089A1/en
Application filed by Lead Billion Ltd filed Critical Lead Billion Ltd
Application granted granted Critical
Publication of DK1848445T3 publication Critical patent/DK1848445T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (10)

1. Anvendelse af en isoleret forbindelse med formel (I) ved fremstilling af et medikament til behandling af koronar hjertesygdom eller hjerteinfarkt i et forsøgspattedyr.
Formel I.
2. Anvendelse ifølge krav 1, hvor forbindelsen udøver en terapeutisk effekt ved revaskularisering i et infarceret hjertevæv i forsøgspattedyret.
3. Anvendelse ifølge krav 2, hvor revaskulariseringen sker inden for 24 til 72 timer efter en behandling med forbindelsen.
4. Anvendelse ifølge krav 1, hvor den koronare hjertesygdom eller hjertein-farktet skyldes aterosklerose af koronare arterier.
5. Anvendelse af en isoleret forbindelse med formel (I) ifølge krav 1 ved fremstilling af et medikament til revaskularisering i infarcerede hjertemuskler i et forsøgspattedyr.
6. Anvendelse ifølge krav 5, hvor forbindelsen opregulerer ekspression af VEGFogbFGF.
7. Anvendelse ifølge krav 5, hvor forbindelsen injiceres direkte i væv i de infarcerede hjertemuskler.
8. Anvendelse ifølge krav 5, hvor forbindelsen indføres i væv i de infarcerede hjertemuskler via oral indgivelse.
9. Anvendelse ifølge krav 5, hvor forbindelsen indføres i væv i de infarcerede hjertemuskler via subkutan injektion, intramuskulær injektion eller intravenøs infusion.
10. Isoleret forbindelse med formel (I) ifølge krav 1 til anvendelse ved behandling af koronar hjertesygdom eller hjerteinfarkt i et forsøgspattedyr og/eller til revaskularisering i infarcerede hjertemuskler i et forsøgspattedyr.
DK06805091.3T 2005-10-27 2006-10-27 Farmaceutisk sammensætning og fremgangsmåde til neoangiogenese/revaskularisering, som er anvendelige ved behandling af iskæmiske hjertesygdomme DK1848445T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB2005/003191 WO2007049088A1 (en) 2005-10-27 2005-10-27 Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
PCT/IB2005/003202 WO2007049089A1 (en) 2005-10-27 2005-10-27 Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
US79146206P 2006-04-13 2006-04-13
PCT/CN2006/002886 WO2007048353A1 (en) 2005-10-27 2006-10-27 Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases

Publications (1)

Publication Number Publication Date
DK1848445T3 true DK1848445T3 (da) 2015-05-26

Family

ID=37967417

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06805090.5T DK1848440T3 (da) 2005-10-27 2006-10-27 Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader
DK06805091.3T DK1848445T3 (da) 2005-10-27 2006-10-27 Farmaceutisk sammensætning og fremgangsmåde til neoangiogenese/revaskularisering, som er anvendelige ved behandling af iskæmiske hjertesygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06805090.5T DK1848440T3 (da) 2005-10-27 2006-10-27 Farmaceutisk sammensætning og fremgangsmåde til regenerering af myofibre i behandlingen af muskelskader

Country Status (10)

Country Link
US (6) US9155744B2 (da)
EP (2) EP1848440B1 (da)
JP (2) JP5117386B2 (da)
CN (1) CN101137387B (da)
AU (2) AU2006308338B2 (da)
CA (2) CA2593161C (da)
DK (2) DK1848440T3 (da)
ES (2) ES2540912T3 (da)
HK (2) HK1110784A1 (da)
WO (2) WO2007048353A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5117386B2 (ja) 2005-10-27 2013-01-16 リード ビリオン リミテッド 筋傷害の治療における筋線維の再生のための医薬組成物及び方法
CN102573865B (zh) 2009-06-12 2016-08-24 基因雷克斯制药有限公司 用于预防和治疗红细胞聚集的组合物
AU2011349207A1 (en) * 2010-12-23 2013-07-11 Huya Bioscience International Llc Purified cardiogenin isomer and related methods
WO2012107202A1 (en) * 2011-02-08 2012-08-16 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Sweetener, sweetener compositions, methods of making the same and consumables containing the same
WO2013171100A1 (en) * 2012-05-16 2013-11-21 Joachim Hans Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
JP6024880B2 (ja) * 2012-09-03 2016-11-16 国立大学法人東北大学 環状デプシペプチドの新規使用方法
LU101117B1 (en) 2019-02-07 2020-08-07 Luxembourg Institute Of Science And Tech (List) METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS
WO2023129377A1 (en) * 2022-01-03 2023-07-06 The Johns Hopkins University Methods and materials for treating heart attack
KR102645399B1 (ko) * 2022-07-25 2024-03-11 코스맥스엔에스 주식회사 유스카픽 에시드를 포함하는 근 기능 개선 또는 근육 질환 예방, 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62129220A (ja) * 1985-11-30 1987-06-11 Riide Chem Kk 制癌剤
JPS646289A (en) * 1987-06-29 1989-01-10 Lead Chem Co Ltd Pharmaceutical composition for remedy and crisis-prevention of acquired immunodeficiency syndrome
JPH0881489A (ja) * 1994-07-15 1996-03-26 Sagami Chem Res Center ポリガラクツロナーゼ阻害剤
US5916919A (en) * 1997-06-27 1999-06-29 Dalhousie University Retrovirus protease inhibitors
JP2001335503A (ja) * 2000-05-29 2001-12-04 Teika Seiyaku Kk ラジカル消去用医薬品
CN1258371C (zh) * 2001-11-21 2006-06-07 香港中文大学 包括大根草有机提取物的组合物及其应用
EP1569668B1 (en) * 2002-12-10 2011-07-20 Lead Billion Limited An organic extract of geum japonicum thumb variant and use thereof
US20070053839A1 (en) * 2003-06-12 2007-03-08 Jianyi Zhang Directing cells to target tissues organs
CN1325055C (zh) * 2003-10-24 2007-07-11 中山大学 甜叶甙r1及其衍生物在制备防治帕金森病的药物中的应用
CN1582946B (zh) 2004-06-09 2010-04-28 北京苏里曼医药科技有限公司 积雪草酸衍生物在制备防治心、脑血管疾病的药物中的用途
CN100467025C (zh) 2004-06-09 2009-03-11 北京苏里曼医药科技有限公司 积雪草总苷、积雪草苷或羟基积雪草苷在制备防治心、脑血管疾病药物中的用途
CN100531740C (zh) 2004-06-10 2009-08-26 北京苏里曼医药科技有限公司 一种辅助防治心、脑血管疾病的保健品
JP5117386B2 (ja) 2005-10-27 2013-01-16 リード ビリオン リミテッド 筋傷害の治療における筋線維の再生のための医薬組成物及び方法
WO2007049088A1 (en) 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
WO2007049089A1 (en) 2005-10-27 2007-05-03 Lead Billion Limited Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues

Also Published As

Publication number Publication date
US20160058797A1 (en) 2016-03-03
ES2540912T3 (es) 2015-07-14
JP2009520683A (ja) 2009-05-28
CN101137387B (zh) 2011-05-25
WO2007048352A1 (en) 2007-05-03
US20170189432A1 (en) 2017-07-06
CA2593171C (en) 2012-05-08
CN101137387A (zh) 2008-03-05
US20080124388A1 (en) 2008-05-29
AU2006308338B2 (en) 2009-11-05
EP1848440B1 (en) 2013-07-17
DK1848440T3 (da) 2013-09-23
AU2006308338A1 (en) 2007-05-03
CA2593161A1 (en) 2007-05-03
WO2007048353A1 (en) 2007-05-03
JP4950996B2 (ja) 2012-06-13
US20190358251A1 (en) 2019-11-28
EP1848445A1 (en) 2007-10-31
AU2006308337A1 (en) 2007-05-03
HK1112848A1 (en) 2008-09-19
EP1848440A1 (en) 2007-10-31
US20090028959A1 (en) 2009-01-29
ES2427354T3 (es) 2013-10-30
JP5117386B2 (ja) 2013-01-16
US9155744B2 (en) 2015-10-13
EP1848445B1 (en) 2015-04-01
US20220152070A1 (en) 2022-05-19
EP1848445A4 (en) 2010-07-21
HK1110784A1 (en) 2008-07-25
CA2593161C (en) 2011-09-13
EP1848440A4 (en) 2010-07-21
WO2007048352B1 (en) 2007-06-14
JP2009520684A (ja) 2009-05-28
WO2007048353B1 (en) 2007-06-07
CA2593171A1 (en) 2007-05-03
AU2006308337B2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
US20220152070A1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart disease
US7709031B2 (en) Angiogenic agents from plant extracts, gallic acid, and derivatives
Chen et al. Isodunnianol alleviates doxorubicin-induced myocardial injury by activating protective autophagy
US20210268010A1 (en) Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart disease
Meng et al. Ganoderma Lucidum Polysaccharide Peptide attenuates post myocardial infarction fibrosis via down-regulating TGF-β1/SMAD and relieving oxidative stress
EP3320901B1 (en) Dimethylaminomicheliolide for use in the treatment of pulmonary fibrosis
WO2023082238A1 (zh) 预防和治疗哺乳动物缺血性心脏病的药物和制备方法及应用
Chen et al. Ginkgo biloba extract protects mesenteric arterioles of old rats via improving vessel elasticity through akt/FoxO3a signaling pathway
Yin et al. Effect of traditional Chinese medicine Shu-Mai-Tang on attenuating TNFα-induced myocardial fibrosis in myocardial ischemia rats
JP2003506487A (ja) タンパク質チロシンホスファターゼインヒビター（ｐｔｐ）としてのペルオキソバナジウム化合物、血管形成、再狭窄およびエンドセリン産生に対するそれらの阻害作用、並びに免疫応答に対するそれらの刺激作用
Gu et al. Neovascularization of ischemic myocardium by newly isolated tannins prevents cardiomyocyte apoptosis and improves cardiac function
US7572467B2 (en) Compositions comprising organic extracts of Geum japonicum thunb var. and the use thereof
US20220175806A1 (en) Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries
CN115919850B (zh) 一种抗阿霉素心脏毒性的中药单体组合物及其制备方法和应用
CN114917346B (zh) 用于缺血性心脏病治疗的药物及药物组合物
CN113491757B (zh) 一种中药组合物在制备防治骨质疏松症药物中的应用
SUNG et al. Repair of Infarcted Myocardium by an Extract of Geum Japonicum with Dual Effects on Angiogenesis and Myogenesis